142337-95-9

Usage

Uses

Used in Chemical Industry:
Pyridine, 3-bromo-5-ethyl(9CI) is utilized as an intermediate in the synthesis of various chemical compounds, contributing to the development of new materials and products. Its unique structure and reactivity make it a valuable component in the creation of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Scientific Research:
In the field of scientific research, Pyridine, 3-bromo-5-ethyl(9CI) serves as a key building block for the preparation of complex organic molecules. Researchers use Pyridine, 3-bromo-5-ethyl- (9CI) to explore its potential applications in the synthesis of novel compounds with specific properties, such as improved biological activity or enhanced stability. Pyridine, 3-bromo-5-ethyl(9CI)'s versatility in chemical reactions allows scientists to investigate its role in various chemical processes and mechanisms.

InChI:InChI=1/C7H8BrN/c1-2-6-3-7(8)5-9-4-6/h3-5H,2H2,1H3

Upstream product

• 38940-62-4 3-acetyl-5-bromopyridine 
• 625-92-3 3,5-dibromopyridine 
• 4433-63-0 Ethyl boronic acid 
• 536-78-7 3-ethylpyridine 

Downstream Products

• 98664-63-2 3-ethyl-5-formylpyridine 

Relevant academic research and scientific papers

Studies on the Nucleophilic Addition to 3,5-Disubstituted Pyridinium Salts

The reactivity of pyridinium salts 2 towards nucleophiles has been studied.The interaction with enolates derived from esters 1 gave only trace amounts of the expected compounds 3.Irreversible-type additions, however, allowed the preparation of indolyldihydropyridines 8 and 9 with high yields.Reaction of organometallic 10 with salt 2c, followed by acidic cyclization, afforded tetracycle 12.

BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS

Phosphatidylinositol (PI) 3-kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.

INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH

Provided herein are compounds having TNFα and/or PDE4 and/or B-RAF inhibitory activity, and compositions thereof. In particular, provided herein are compounds of the formula (I) and pharmaceutically acceptable salts, solvates, hydrates, clathrates, stereoisomers, polymorphs and prodrugs thereof, wherein Ar, R1, R2, R3, R4, n and Z are as described herein. Further provided herein are methods for treating or preventing various diseases and disorders by administering to a patient one or more TNFα and/or PDE4 and/or B-RAF inhibitors. In particular, provided herein are methods for preventing or treating cancer, inflammatory disorders, cognition and memory disorders and autoimmune disorders, or one or more symptoms thereof by administering to a patient one or more TNFα and/or PDE4 and/or B-RAF inhibitors.

INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME

The present invention provides compounds of formula (4), and their pharmaceutically acceptable salts and solvates, which are useful as inhibitors of the Hepatitis C virus (HCV) polymerase enzyme and are also useful for the treatment of HCV infections in HCV-infected mammals. The present invention also provides pharmaceutical compositions comprising compounds of formula (4), their pharmaceutically acceptable salts and solvates. Furthermore, the present invention provides intermediate compounds and methods useful in the preparation of compounds of formula (4).

INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME

The invention relates to compounds of the formula (I) and to pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z, R1and R2, are as defined herein. The invention also relates to methods of treating Hepatitis C virus in mammals by administering the compounds of formula (I), and to pharmaceutical compositions for treating such disorders, which contain the compounds of formula (I). The invention also relates to methods of preparing the compounds of formula (I).